Zosuquidar
drugOn this page
Also known as LY335979 (Zosuquidar trihydrochloride)
Summary
Zosuquidar (CHEMBL444172) is a phase-3 clinical-stage small molecule targeting ABCB1; indicated across 1 condition including leukemia.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Targets: 1 (ABCB1)
- Indications: 1 condition
- Clinical trials: 2
- Chemistry: 527.6 Da · C32H31F2N3O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL444172 |
| Name | Zosuquidar |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 3036703 |
| Molecular formula | C32H31F2N3O2 |
| Molecular weight | 527.6 |
| InChIKey | IHOVFYSQUDPMCN-XAKVHENESA-N |
SMILES: C1CN(CCN1C[C@H](COC2=CC=CC3=C2C=CC=N3)O)C4C5=CC=CC=C5[C@H]6[C@H](C6(F)F)C7=CC=CC=C47
IUPAC name: (2R)-1-[4-[(2S,4R)-3,3-difluoro-11-tetracyclo[10.4.0.02,4.05,10]hexadeca-1(16),5,7,9,12,14-hexaenyl]piperazin-1-yl]-3-quinolin-5-yloxypropan-2-ol
Also known as: Zosuquidar, ZOSUQUIDAR, LY335979 (Zosuquidar trihydrochloride)
Parent form; salt/anhydrous children: CHEMBL2074689
Patent coverage: 19 distinct patent families (32 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 27 (84%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| ABCB1 | ABCB1 | Inhibition | 7.23 | 0.4% | P08183 |
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: ATP-dependent translocase ABCB1.
Bioactivity
ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| ABCB1 | 7.23 | IC50 | 58.88 | nM | CHEMBL_ACT_10954676 |
Target pathways
Aggregated over 1 target gene(s): ABCB1.
Top Reactome pathways
7 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Abacavir transmembrane transport | 1 | ABCB1 |
| Abacavir ADME | 1 | ABCB1 |
| Transport of small molecules | 1 | ABCB1 |
| ABC-family protein mediated transport | 1 | ABCB1 |
| Drug ADME | 1 | ABCB1 |
| Atorvastatin ADME | 1 | ABCB1 |
| Prednisone ADME | 1 | ABCB1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| G2/M transition of mitotic cell cycle | 1 |
| response to hypoxia | 1 |
| placenta development | 1 |
| xenobiotic metabolic process | 1 |
| female pregnancy | 1 |
| lactation | 1 |
| circadian rhythm | 1 |
| response to xenobiotic stimulus | 1 |
| hormone transport | 1 |
| response to progesterone | 1 |
| response to vitamin A | 1 |
| response to vitamin D | 1 |
| response to glucagon | 1 |
| maintenance of blood-brain barrier | 1 |
| cellular response to mycotoxin | 1 |
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| leukemia | 1 | MONDO:0005059 | EFO:0000565 |
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00129168 | PHASE1/PHASE2 | COMPLETED | Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) |
| NCT00233909 | PHASE1/PHASE2 | COMPLETED | A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
122 molecules share ≥1 primary target. Top 60 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| TRAMETINIB | ChEMBL + PubChem | Phase 4 (approved) | ABCB1 |
| AMIODARONE | ChEMBL | Phase 4 (approved) | ABCB1 |
| AMLODIPINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| ARIPIPRAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| ASTEMIZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| ATAZANAVIR | ChEMBL | Phase 4 (approved) | ABCB1 |
| AZELASTINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| BROMOCRIPTINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| CARVEDILOL | ChEMBL | Phase 4 (approved) | ABCB1 |
| CERITINIB | ChEMBL | Phase 4 (approved) | ABCB1 |
| CHLORPROMAZINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| CLARITHROMYCIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| CLOFAZIMINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| CLOTRIMAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| CYCLOSPORINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| DARUNAVIR | ChEMBL | Phase 4 (approved) | ABCB1 |
| DAUNORUBICIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| DESLORATADINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| DILTIAZEM | ChEMBL | Phase 4 (approved) | ABCB1 |
| DIPYRIDAMOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| DONEPEZIL | ChEMBL | Phase 4 (approved) | ABCB1 |
| DOXORUBICIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| EBASTINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| EMETINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| ERGOTAMINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| ERLOTINIB | ChEMBL | Phase 4 (approved) | ABCB1 |
| ERYTHROMYCIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| ETRAVIRINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| FELODIPINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| FENTANYL | ChEMBL | Phase 4 (approved) | ABCB1 |
| FLUPHENAZINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| GEFITINIB | ChEMBL | Phase 4 (approved) | ABCB1 |
| HALOPERIDOL | ChEMBL | Phase 4 (approved) | ABCB1 |
| IMATINIB | ChEMBL | Phase 4 (approved) | ABCB1 |
| INDOMETHACIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| ITRACONAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| IVERMECTIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| KETOCONAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| LANSOPRAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| LEFAMULIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| LONAFARNIB | ChEMBL | Phase 4 (approved) | ABCB1 |
| LOPERAMIDE | ChEMBL | Phase 4 (approved) | ABCB1 |
| LOPINAVIR | ChEMBL | Phase 4 (approved) | ABCB1 |
| LORATADINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| LOVASTATIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| METHADONE | ChEMBL | Phase 4 (approved) | ABCB1 |
| MIBEFRADIL | ChEMBL | Phase 4 (approved) | ABCB1 |
| MICONAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| MIDOSTAURIN | ChEMBL | Phase 4 (approved) | ABCB1 |
| MITOXANTRONE | ChEMBL | Phase 4 (approved) | ABCB1 |
| NEFAZODONE | ChEMBL | Phase 4 (approved) | ABCB1 |
| NELFINAVIR | ChEMBL | Phase 4 (approved) | ABCB1 |
| NICARDIPINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| NINTEDANIB | ChEMBL | Phase 4 (approved) | ABCB1 |
| NISOLDIPINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| OMEPRAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| PACLITAXEL | ChEMBL | Phase 4 (approved) | ABCB1 |
| PANTOPRAZOLE | ChEMBL | Phase 4 (approved) | ABCB1 |
| PAROXETINE | ChEMBL | Phase 4 (approved) | ABCB1 |
| PIMOZIDE | ChEMBL | Phase 4 (approved) | ABCB1 |
Related Atlas pages
- Genes: ABCB1
- Drugs: Trametinib, Amiodarone, Amlodipine, Aripiprazole, Astemizole, Atazanavir, Azelastine, Bromocriptine, Carvedilol, Ceritinib, Chlorpromazine, Clarithromycin, Clofazimine, Clotrimazole, Cyclosporine, Darunavir, Daunorubicin, Desloratadine, Diltiazem, Dipyridamole, Donepezil, Doxorubicin, Ebastine, Emetine, Ergotamine, Erlotinib, Erythromycin, Etravirine, Felodipine, Fentanyl, Fluphenazine, Gefitinib, Haloperidol, Imatinib, Indomethacin, Itraconazole, Ivermectin, Ketoconazole, Lansoprazole, Lefamulin, Lonafarnib, Loperamide, Lopinavir, Loratadine, Lovastatin, Methadone, Mibefradil, Miconazole, Midostaurin, Mitoxantrone, Nefazodone, Nelfinavir, Nicardipine, Nintedanib, Nisoldipine, Omeprazole, Paclitaxel, Pantoprazole, Paroxetine, Pimozide